Impact of Elexacaftor/Tezacaftor/Ivacaftor Therapy on the Cystic Fibrosis Airway Microbial Metagenome

被引:20
|
作者
Pallenberg, Sophia T. [1 ,2 ]
Pust, Marie-Madlen [1 ,2 ,4 ]
Rosenboom, Ilona [1 ]
Hansen, Gesine [1 ,2 ]
Wiehlmann, Lutz [3 ]
Dittrich, Anna-Maria [1 ,2 ]
Tummler, Burkhard [1 ,2 ]
机构
[1] Hannover Med Sch, Dept Pediat Pneumol Allergol & Neonatol, Hannover, Germany
[2] Hannover Med Sch, German Ctr Lung Res Biomed Res Endstage & Obstruc, Hannover, Germany
[3] Hannover Med Sch, Res Core Unit Genom, Hannover, Germany
[4] Broad Inst MIT & Harvard, Cambridge, MA 02142 USA
来源
MICROBIOLOGY SPECTRUM | 2022年 / 10卷 / 05期
关键词
CFTR modulation; ELX; TEZ; IVA; airway metagenome; cystic fibrosis; metagenomics; whole-genome sequencing; DOUBLE-BLIND; IVACAFTOR; EFFICACY; SAFETY; SAMPLES; PEOPLE;
D O I
10.1128/spectrum.01454-22
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Shotgun metagenome sequencing of respiratory secretions with spike-in controls for normalization demonstrated that 1 year of high-efficient CFTR modulation with elexacaftor/tezacaftor/ivacaftor extensively reduced the bacterial load. Longer observation periods will be necessary to resolve whether the partial reversion of the basic defect that is achieved with ELX/TEZ/IVA is sufficient in the long run to render the CF lungs robust against the recolonization with common opportunistic pathogens. The introduction of mutation-specific combination therapy with the cystic fibrosis transmembrane conductance regulator (CFTR) modulators elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) has substantially improved lung function and quality of life of people with cystic fibrosis (CF). Collecting deep cough swabs and induced sputum, this postapproval study examined the effect of 14- and 50-week treatment with ELX/TEZ/IVA on the airway microbial metagenome of pancreatic- insufficient CF patients aged 12 years and older. Compared to pretreatment, the total bacterial load decreased, the individual species were more evenly distributed in the community, and the individual microbial metagenomes became more similar in their composition. However, the microbial network remained vulnerable to fragmentation. The initial shift of the CF metagenome was attributable to the ELX/TEZ/IVA-mediated gain of CFTR activity followed by a diversification driven by a group of commensals at the 1-year time point that are typical for healthy airways. IMPORTANCE Shotgun metagenome sequencing of respiratory secretions with spike-in controls for normalization demonstrated that 1 year of high-efficient CFTR modulation with elexacaftor/tezacaftor/ivacaftor extensively reduced the bacterial load. Longer observation periods will be necessary to resolve whether the partial reversion of the basic defect that is achieved with ELX/TEZ/IVA is sufficient in the long run to render the CF lungs robust against the recolonization with common opportunistic pathogens.
引用
收藏
页数:16
相关论文
共 50 条
  • [1] Cystic Fibrosis: Triple Therapy with Elexacaftor, Tezacaftor and Ivacaftor
    Lorenz, Judith
    PNEUMOLOGIE, 2022, 76 (03): : 153 - 153
  • [2] Unveiling the psychosocial impact of Elexacaftor/Tezacaftor/Ivacaftor therapy in Cystic Fibrosis patients
    Garcia, Marta Solis
    Pelaez, Adrian
    Punter, Rosa Mar Gomez
    Lopez, Maria Criado
    Carbajal, Claudia Madrid
    Ancochea, Julio
    Bachiller, Jose Maria Eiros
    Hernandez, Ana Sofia Martin
    Rodrigo-Garcia, Maria
    Clemente, Marta Garcia
    Moreno, Rosa Ma Giron
    BMC PULMONARY MEDICINE, 2025, 25 (01):
  • [3] Effect of elexacaftor/tezacaftor/ivacaftor on airway and systemic inflammation in cystic fibrosis
    Casey, Michelle
    Gabillard-Lefort, Claudie
    McElvaney, Oisin F.
    McElvaney, Oliver J.
    Carroll, Tomas
    Heeney, Ronan C.
    Gunaratnam, Cedric
    Reeves, Emer P.
    Murphy, Mark P.
    McElvaney, Noel G.
    THORAX, 2023, 78 (08) : 835 - 839
  • [4] Impact of Elexacaftor/Tezacaftor/Ivacaftor on airway inflammation and clinical outcomes in Patients with Cystic Fibrosis
    Casey, Michelle
    Gabillard-Lefort, Claudie
    Kerr, Orla
    Marron, Elaine
    Lyons, Anne-Marie
    Cullen, Lydia
    Murphy, Alexandra
    Gunaratnam, Cedric
    Reeves, Emer P.
    McElvaney, Noel G.
    IRISH JOURNAL OF MEDICAL SCIENCE, 2021, 190 (SUPPL 5) : 179 - 179
  • [5] Impact of extended Elexacaftor/Tezacaftor/Ivacaftor therapy on the gut microbiome in cystic fibrosis
    Marsh, Ryan
    Dos Santos, Claudio
    Yule, Alexander
    Dellschaft, Neele S.
    Hoad, Caroline L.
    Ng, Christabella
    Major, Giles
    Smyth, Alan R.
    Rivett, Damian
    van der Gast, Christopher
    JOURNAL OF CYSTIC FIBROSIS, 2024, 23 (05) : 967 - 976
  • [6] Impact of elexacaftor/tezacaftor/ivacaftor on depression and anxiety in cystic fibrosis
    Zhang, Lijia
    Albon, Dana
    Jones, Marieke
    Bruschwein, Heather
    THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE, 2022, 16
  • [7] Elexacaftor/tezacaftor/ivacaftor treatment reduces airway inflammation in cystic fibrosis
    De Vuyst, Richard C.
    Bennard, Erin
    Kam, Charissa W.
    McKinzie, Cameron J.
    Esther, Charles R.
    PEDIATRIC PULMONOLOGY, 2023, 58 (05) : 1592 - 1594
  • [8] Impact of elexacaftor/tezacaftor/ivacaftor on depression and anxiety in cystic fibrosis
    Zhang, Lijia
    Albon, Dana
    Jones, Marieke
    Bruschwein, Heather
    THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE, 2022, 16
  • [9] Elexacaftor/Tezacaftor/Ivacaftor (Trikafta) for Cystic Fibrosis
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2020, 62 (1589): : 5 - 7
  • [10] Elexacaftor/Tezacaftor/Ivacaftor Accelerates Wound Repair in Cystic Fibrosis Airway Epithelium
    Laselva, Onofrio
    Conese, Massimo
    JOURNAL OF PERSONALIZED MEDICINE, 2022, 12 (10):